midazolam has been researched along with Neoplasms in 98 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 9.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| "Sixty-three ambulatory patients with advanced cancer and dyspnea were clinically characterized and then randomized to receive either oral morphine or oral midazolam." | 9.14 | Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. ( Castro, MA; Cerchietti, LC; Navigante, AH, 2010) |
| "With the introduction of midazolam, 73% of patients had a reduction of at least one grade in nausea and vomiting intensity in comparison with the previous cycle of chemotherapy." | 9.11 | Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. ( Barni, S; Cabiddu, M; Cazzaniga, M; Cremonesi, M; Di Cosimo, S; Ferretti, G; Ghilardi, M; Mandalà, M; Rocca, A, 2005) |
| "Parents and nurses reported reduced anxiety, discomfort, and procedure problems for children in the midazolam group and would prefer the same medication at next procedure." | 9.09 | Midazolam nasal spray reduces procedural anxiety in children. ( Andréasson, S; Gordh, T; Kreuger, A; Ljungman, G; Sörensen, S, 2000) |
| "Midazolam, a short-acting benzodiazepine used for preoperative anxiolysis, may also have pharmacologic properties that could further reduce the incidence of postoperative nausea and vomiting (PONV) in high-risk patients when included in a multimodal antiemetic protocol." | 7.91 | Effects of Midazolam on Postoperative Nausea and Vomiting and Discharge Times in Outpatients Undergoing Cancer-Related Surgery. ( Assel, M; Cansino, C; Long, M; Majumdar, JR; Twersky, R; Vertosick, E, 2019) |
| "We evaluated the safety and efficacy of midazolam-ketamine association to control pain induced by diagnostic procedures in paediatric oncology patients." | 7.70 | Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. ( Granry, JC; Le Moine, P; Monrigal, JP; Pellier, I; Rialland, X; Rod, B, 1999) |
| "Midazolam was found to be the drug of preference for the majority of patients." | 6.67 | Midazolam versus fentanyl as premedication for painful procedures in children with cancer. ( Conner, K; Dickson, N; Luzins, J; McGorray, S; Reilly, K; Sandler, ES; Weyman, C, 1992) |
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 5.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| "Sixty-three ambulatory patients with advanced cancer and dyspnea were clinically characterized and then randomized to receive either oral morphine or oral midazolam." | 5.14 | Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. ( Castro, MA; Cerchietti, LC; Navigante, AH, 2010) |
| "With the introduction of midazolam, 73% of patients had a reduction of at least one grade in nausea and vomiting intensity in comparison with the previous cycle of chemotherapy." | 5.11 | Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. ( Barni, S; Cabiddu, M; Cazzaniga, M; Cremonesi, M; Di Cosimo, S; Ferretti, G; Ghilardi, M; Mandalà, M; Rocca, A, 2005) |
| "Parents and nurses reported reduced anxiety, discomfort, and procedure problems for children in the midazolam group and would prefer the same medication at next procedure." | 5.09 | Midazolam nasal spray reduces procedural anxiety in children. ( Andréasson, S; Gordh, T; Kreuger, A; Ljungman, G; Sörensen, S, 2000) |
| "Midazolam, a short-acting benzodiazepine used for preoperative anxiolysis, may also have pharmacologic properties that could further reduce the incidence of postoperative nausea and vomiting (PONV) in high-risk patients when included in a multimodal antiemetic protocol." | 3.91 | Effects of Midazolam on Postoperative Nausea and Vomiting and Discharge Times in Outpatients Undergoing Cancer-Related Surgery. ( Assel, M; Cansino, C; Long, M; Majumdar, JR; Twersky, R; Vertosick, E, 2019) |
| " In univariate analysis, high midazolam concentration and free DCX AUC were associated with severe neutropenia and FN." | 3.74 | Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. ( Alexandre, J; Dieras, V; Girre, V; Goldwasser, F; Grabar, S; Hérait, P; Jullien, V; Montheil, V; Pons, G; Rabillon, F; Rey, E; Tran, A; Treluyer, JM, 2007) |
| " At the initial surgery, children were assigned (no parental intervention) to receive oral midazolam (n = 13), or parental presence during the induction of anesthesia (PPIA, n = 27), or PPIA + midazolam (n = 10) or no intervention (n = 33)." | 3.72 | Parental intervention choices for children undergoing repeated surgeries. ( Caldwell-Andrews, AA; Kain, ZN; Krivutza, DM; Mayes, LC; Wang, SM; Weinberg, ME, 2003) |
| "We evaluated the safety and efficacy of midazolam-ketamine association to control pain induced by diagnostic procedures in paediatric oncology patients." | 3.70 | Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. ( Granry, JC; Le Moine, P; Monrigal, JP; Pellier, I; Rialland, X; Rod, B, 1999) |
| " After cocktail alone or in combination with adavosertib administration, 24-h pharmacokinetic sampling occurred for probe substrates and their respective metabolites paraxanthine, 5-hydroxyomeprazole (5-HO), and 1'-hydroxymidazolam (1'-HM)." | 3.30 | Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. ( Ah-See, ML; Edenfield, WJ; Lewis, LD; Li, Y; Mugundu, GM; Nadeau, L; Någård, M; Ottesen, LH; Safran, HP; Strauss, J; Wise-Draper, T, 2023) |
| " The efficacy and safety of the sedations including sedation time intervals, nausea score, vomiting episodes, pain score, adverse effects, and parent's satisfaction were evaluated." | 3.11 | The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial. ( Lertvivatpong, N; Malaithong, W; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Traivaree, C, 2022) |
| " There was little change in the terminal elimination phase half-life of midazolam when administered with lenvatinib." | 2.94 | An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors. ( Aluri, J; Dutcus, CE; He, C; Rance, C; Ren, M; Shumaker, R, 2020) |
| "Fedratinib is a weak inhibitor of CYP2D6, and a moderate inhibitor of CYP2C19 and CYP3A4." | 2.94 | Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. ( Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J, 2020) |
| "In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated." | 2.90 | Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ( Bardenheuer, HJ; Burhenne, J; Geist, MJP; Mikus, G; Skopp, G; Ziesenitz, VC, 2019) |
| " inclusion/exclusion criteria, combination study design), we used human hepatocyte data and physiologically-based pharmacokinetic (PBPK) modelling to predict its CYP3A4-mediated DDI potential." | 2.90 | Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. ( Cutler, RE; Gore, L; Harvey, RD; Mita, A; Ou, Y; Papadopoulos, KP; Pinchasik, DE; Tsimberidou, AM; Wang, Z; Xu, Y, 2019) |
| "This phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib and P-glycoprotein." | 2.87 | Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. ( Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H, 2018) |
| "Patients with cancer (n=24) received a single oral dose of 7." | 2.79 | Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. ( Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C, 2014) |
| "We aim to evaluate the influence of covariates, including cytochrome P450 3A (CYP3A) genetic polymorphisms, on the pharmacokinetics of midazolam (MDZ) in Asian cancer patients, using a population pharmacokinetic approach." | 2.79 | CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients. ( Goh, BC; Hee, KH; Lee, LS; Sapari, NS; Seng, KY; Soon, GH; Soong, R, 2014) |
| "Sunitinib PK was evaluated in eight cancer patients receiving sunitinib monotherapy in a "4 weeks on-2 weeks off" dose regimen." | 2.76 | Marginal increase of sunitinib exposure by grapefruit juice. ( Baker, SD; Chen, Z; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; König-Quartel, JM; Ploeger, BA; van Erp, NP; Zandvliet, AS, 2011) |
| "Vinflunine is a novel vinca alkaloid with promising single agent clinical activity." | 2.76 | Phase I trial of vinflunine and pemetrexed in refractory solid tumors. ( Buie, L; Chiu, WK; Davies, J; Dees, EC; Ivanova, A; Keller, K; O'Neil, B; Sanoff, HK; Stinchcombe, TE; Walko, C, 2011) |
| "Neutropenia was the dose-limiting toxicity." | 2.73 | A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008) |
| " Midazolam concentrations in plasma were determined using liquid chromatography-mass spectrometry, and pharmacokinetic variables were calculated using noncompartmental analysis." | 2.71 | Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. ( Ahn, D; Baker, SD; Bates, SE; Cusatis, G; Figg, WD; Ingersoll, RG; Lepper, ER; Mathijssen, RH; Permenter, M; Price, DK; Ries, N; Schenk, PW; Smith, NF; Sparreboom, A; van Schaik, RH; Verweij, J, 2005) |
| "Midazolam is a useful drug used preoperatively because it can produce anxiolysis and sedation." | 2.70 | [Effects of midazolam premedication on induction doses of propofol and hemodynamic changes during tumor patient induction]. ( Lin, WQ; Tan, HY; Wang, J; Xu, MX; Zeng, WA, 2002) |
| "48 terminal cancer patients suffering from chronic pain." | 2.69 | Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. ( Gomes, JM; Lauretti, GR; Pereira, NL; Reis, MP, 1999) |
| "Midazolam is an effective benzodiazepine with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations." | 2.67 | Midazolam in patients receiving anticancer chemotherapy and antiemetics. ( Baltzer, L; Clark, RA; Gralla, RJ; Kris, MG; Pisters, KM; Potanovich, LM; Tyson, LB, 1993) |
| "Midazolam was found to be the drug of preference for the majority of patients." | 2.67 | Midazolam versus fentanyl as premedication for painful procedures in children with cancer. ( Conner, K; Dickson, N; Luzins, J; McGorray, S; Reilly, K; Sandler, ES; Weyman, C, 1992) |
| " These findings suggest that differential affinities for solute carriers should be considered when selecting an appropriate phenotypic probe to allow tailored dosing of pharmaceuticals that are CYP3A4 substrates." | 2.44 | Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. ( Baker, SD; Franke, RM; Mathijssen, RH; Schuetz, EG; Sparreboom, A, 2008) |
| "The most common cancer types were lung and gastro-intestinal carcinomas (27% and 21% respectively)." | 1.72 | The quality of palliative sedation in end-stage disease: audit from a department of oncology and haematology. ( Alessia, S; Chiara, C; Chrystel, I; Claudia, F; Daniele, D; Flavia, C; Giuseppe, L; Leonardo, F; Leonardo, P; Mario, L; Massimiliano, S; Massimo, D; Matilde, SF; Raffaella, P, 2022) |
| " Accordingly, the bioavailability of midazolam was increased by about 3 times, thus enhancing its pharmacological effect." | 1.62 | Involvement of the Parathyroid Hormone-Related Protein on Changes in the CYP3A Expression in Cancer Cachexia. ( Chikamatsu, M; Fujita, I; Ichimizu, S; Ikegami, K; Imafuku, T; Kobayashi, K; Maeda, H; Maruyama, T; Tanaka, R; Watanabe, H; Yamada, K, 2021) |
| "Midazolam was used in all nine cases." | 1.56 | Continuous deep sedation at the end of life in children with cancer: experience at a single center in Japan. ( Adachi, S; Hiramatsu, H; Kato, I; Maeda, S; Takita, J; Tsuneto, S; Umeda, K, 2020) |
| "Midazolam was used as the first medication for PS, and propofol and phenobarbital were subsequently used as salvage medications." | 1.51 | Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study. ( Chun, HS; Kang, JH; Kim, JH; Kim, RB; Seo, M; Won, YW, 2019) |
| " For both active substances, the dosage necessary to reach sufficient deep analgosedation was significantly higher for patients under 24 months of age." | 1.51 | Bone marrow aspirations in oncological patients: experience from an in-house standard in paediatrics. ( Foell, J; Graeber, S; Lieser, U; Sauer, H, 2019) |
| "During the study period, 552 cancer patients died at the institution and 374 met the inclusion criteria for this study." | 1.48 | Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center. ( Del Giglio, A; Eiger, D; França, MS; Gomes, DBD; Hui, D; Mariano, RC; Prado, BL; Taranto, P; Usón Júnior, PLS, 2018) |
| "At the end of life of cancer patients, sedation is sometimes needed, in order to palliate unbearable symptoms that other treatments fail to relieve." | 1.46 | [Towards a better use of midazolam in end of life: A survey in a department of medical oncology]. ( Beneton, A; Brosse, C; Magné, N; Morisson, S; Pacaut, C; Poenou, G; Vallard, A, 2017) |
| "Lapatinib 1500-mg was administered orally once daily on study days 4 through 11." | 1.46 | The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer. ( Arya, N; Beelen, AP; Coker, SA; Dees, EC; Gainer, SD; Koch, KM; Lewis, LD; Reddy, NJ, 2017) |
| "Delirium was the most frequent reason for PS (n = 15, 75%)." | 1.46 | Bispectral Index monitoring in cancer patients undergoing palliative sedation: a preliminary report. ( Allende-Pérez, S; Bruera, E; García-Salamanca, MF; Hui, D; Monreal-Carrillo, E; Verástegui, E, 2017) |
| "Delirium was assessed using the Nursing Delirium Screening Scale once daily in all cancer patients (N = 100) during their stay on the palliative care unit." | 1.43 | The Impact of Plasma Cholinergic Enzyme Activity and Other Risk Factors for the Development of Delirium in Patients Receiving Palliative Care. ( Bardenheuer, HJ; Frankenhauser, S; Kopitz, J; Petersen, KA; Plaschke, K; Weigand, MA, 2016) |
| "All patients suffered from cancer." | 1.43 | [Palliative sedation at a university palliative care unit--a descriptive analysis]. ( Günther, LD; Hopprich, A; Laufenberg-Feldmann, R; Reinholz, U; Weber, M, 2016) |
| "We analyzed the data of 42 cancer patients (18% of all patients); in 21 cases, PS was initiated (solid tumors n = 11, brain tumors [5], bone tumors [4], leukemia [1])." | 1.40 | Palliative sedation at home for terminally ill children with cancer. ( Fendler, W; Korzeniewska-Eksterowicz, A; Młynarski, W; Przysło, Ł; Stolarska, M, 2014) |
| "Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using a physiologically based pharmacokinetic approach integrating demographic and physiological data from patients with cancer." | 1.39 | A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. ( Budha, NR; Cheeti, S; Dresser, MJ; Jin, JY; Rajan, S, 2013) |
| "Genomic DNA from 108 cancer patients receiving intravenous MDZ and 45 undergoing the erythromycin breath test was analyzed for CYP3A4*22 (rs35599367 C>T) and CYP3A5*3." | 1.39 | CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. ( Charles, KA; Clarke, SJ; de Graan, AJ; Elens, L; Haufroid, V; Mathijssen, RH; Nieuweboer, A; van Schaik, RH, 2013) |
| "Midazolam is a widely used anesthetic of the benzodiazepine class that has shown cytotoxicity and apoptosisinducing activity in neuronal cells and lymphocytes." | 1.39 | Midazolam induces cellular apoptosis in human cancer cells and inhibits tumor growth in xenograft mice. ( Bae, YS; Kang, JH; Kim, HM; Lee, CW; Mishra, SK; Oh, SH; Ryu, JS, 2013) |
| "Etiology of stenosis included lung cancer (46 patients) esophageal cancer (14 patients) and other malignancies (8 patients)." | 1.38 | The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis. ( Anderson, P; McGrath, EE; Warriner, D, 2012) |
| "Midazolam was the drug used in most cases." | 1.38 | A survey of the sedation practice of Portuguese palliative care teams. ( Almeida, A; Barbas, S; Cordero, A; Cruz, A; Feio, M; Gonçalves, F; Neves, S; Rocha, C; Silva, P, 2012) |
| " The dosage range of midazolam in this study fits the recommendations of the Dutch national guideline on palliative sedation, although international studies show smaller dosage ranges." | 1.36 | The practice of continuous palliative sedation in elderly patients: a nationwide explorative study among Dutch nursing home physicians. ( Hasselaar, JG; Koopmans, RT; Krijnsen, PJ; Van Deijck, RH; Verhagen, SC; Vissers, KC, 2010) |
| "Midazolam was used in 18 PS cases (10%)." | 1.35 | Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center. ( Boohene, J; Bruera, E; Calderon, B; Curry Iii, E; Elsayem, A; Hung, F; Munsell, MF, 2009) |
| "All seven had advanced cancer and five of them had metastases to lungs, bone or both." | 1.34 | [Treatment of intolerable sufferings in a hospice unit]. ( Bull, AN; Rosland, JH; Saunes, TK, 2007) |
| "Midazolam and morphine were the two mostly-used drugs; doses used varied considerably." | 1.33 | [Palliative sedation to the dying]. ( Aasland, OG; Førde, R; Kongsgaard, U, 2006) |
| " Posterior Bayesian estimates of vinorelbine clearance were obtained for each patient using population pharmacokinetic modeling." | 1.33 | Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ( Ackland, SP; Balleine, RL; Blair, EY; Clarke, CL; Collins, M; Evans, S; Farlow, D; Garg, MB; Gurney, H; Hoskins, JM; Mann, GJ; McLachlan, AJ; Rivory, LP; Wong, M, 2006) |
| "Midazolam clearance was correlated with dose-normalized plasma midazolam concentrations (concentration/per dose)." | 1.32 | Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. ( Chua, C; Fan, L; Goh, BC; Khoo, YM; Lee, HS; Lim, R; Ong, AB; Wang, L, 2003) |
| "Mean midazolam clearance was 1." | 1.32 | CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. ( Balleine, RL; Clarke, CL; Collins, M; Gurney, H; Liddle, C; Wong, M, 2004) |
| " The mean dosage for midazolam was 18." | 1.32 | Use of sedation to relieve refractory symptoms in dying patients. ( Blitz-Lindeque, J; Bridge, D; Cameron, D, 2004) |
| "In animals without tumors, the temperature subcutaneously on the foot was 0." | 1.29 | Use of the vasodilator sodium nitroprusside during local hyperthermia: effects on tumor temperature and tumor response in a rat tumor model. ( Dahl, O; Krossnes, BK; Mella, O, 1996) |
| "Midazolam (MDZ, Versed) is a water-soluble, rapid-onset, short-duration benzodiazepine that has not been studied widely in children." | 1.28 | Midazolam for conscious sedation during pediatric oncology procedures: safety and recovery parameters. ( Berde, CB; Blanding, PJ; Foley, ME; Sievers, TD; Yee, JD, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (14.29) | 18.2507 |
| 2000's | 29 (29.59) | 29.6817 |
| 2010's | 38 (38.78) | 24.3611 |
| 2020's | 17 (17.35) | 2.80 |
| Authors | Studies |
|---|---|
| Carry, JC | 1 |
| Clerc, F | 1 |
| Minoux, H | 1 |
| Schio, L | 1 |
| Mauger, J | 1 |
| Nair, A | 1 |
| Parmantier, E | 1 |
| Le Moigne, R | 1 |
| Delorme, C | 1 |
| Nicolas, JP | 1 |
| Krick, A | 1 |
| Abécassis, PY | 1 |
| Crocq-Stuerga, V | 1 |
| Pouzieux, S | 1 |
| Delarbre, L | 1 |
| Maignan, S | 1 |
| Bertrand, T | 1 |
| Bjergarde, K | 1 |
| Ma, N | 1 |
| Lachaud, S | 1 |
| Guizani, H | 1 |
| Lebel, R | 1 |
| Doerflinger, G | 1 |
| Monget, S | 1 |
| Perron, S | 1 |
| Gasse, F | 1 |
| Angouillant-Boniface, O | 1 |
| Filoche-Rommé, B | 1 |
| Murer, M | 1 |
| Gontier, S | 1 |
| Prévost, C | 1 |
| Monteiro, ML | 1 |
| Combeau, C | 1 |
| Fujita, I | 1 |
| Watanabe, H | 2 |
| Ikegami, K | 1 |
| Imafuku, T | 1 |
| Ichimizu, S | 1 |
| Chikamatsu, M | 1 |
| Kobayashi, K | 1 |
| Tanaka, R | 1 |
| Yamada, K | 1 |
| Maeda, H | 1 |
| Maruyama, T | 1 |
| Alessia, S | 1 |
| Matilde, SF | 1 |
| Chrystel, I | 1 |
| Massimiliano, S | 1 |
| Daniele, D | 1 |
| Claudia, F | 1 |
| Raffaella, P | 1 |
| Flavia, C | 1 |
| Leonardo, F | 1 |
| Chiara, C | 1 |
| Leonardo, P | 1 |
| Massimo, D | 1 |
| Mario, L | 1 |
| Giuseppe, L | 1 |
| Imai, K | 1 |
| Morita, T | 5 |
| Mori, M | 2 |
| Yokomichi, N | 1 |
| Yamauchi, T | 1 |
| Miwa, S | 1 |
| Inoue, S | 2 |
| Naito, AS | 1 |
| Masukawa, K | 1 |
| Kizawa, Y | 1 |
| Tsuneto, S | 2 |
| Shima, Y | 1 |
| Otani, H | 1 |
| Miyashita, M | 1 |
| Garcia, ACM | 1 |
| Isidoro, GM | 1 |
| Paiva, EMDC | 1 |
| Silva, AE | 1 |
| Costa, ICP | 1 |
| Bornemann-Cimenti, H | 1 |
| Hedman, C | 1 |
| Rosso, A | 1 |
| Häggström, O | 1 |
| Nordén, C | 1 |
| Fürst, CJ | 1 |
| Schelin, MEC | 1 |
| Zhang, S | 1 |
| Gao, T | 1 |
| Fang, B | 1 |
| Abdelemam, RM | 1 |
| Fares, KM | 1 |
| Kamal, SM | 1 |
| Monsereenusorn, C | 1 |
| Malaithong, W | 1 |
| Lertvivatpong, N | 1 |
| Photia, A | 1 |
| Rujkijyanont, P | 1 |
| Traivaree, C | 1 |
| Yasuda, S | 1 |
| Sugano, K | 1 |
| Matsuda, Y | 1 |
| Kako, J | 1 |
| Takagi, Y | 1 |
| Kasahara, Y | 1 |
| Goya, S | 1 |
| Kohara, H | 2 |
| Nakayama, T | 1 |
| Yamaguchi, T | 1 |
| Rijpstra, M | 1 |
| Kuip, E | 1 |
| Hasselaar, J | 1 |
| Vissers, K | 1 |
| Någård, M | 1 |
| Ah-See, ML | 1 |
| Strauss, J | 1 |
| Wise-Draper, T | 1 |
| Safran, HP | 1 |
| Nadeau, L | 1 |
| Edenfield, WJ | 1 |
| Lewis, LD | 2 |
| Ottesen, LH | 1 |
| Li, Y | 1 |
| Mugundu, GM | 1 |
| Bansal, S | 1 |
| Mittal, S | 1 |
| Tiwari, P | 1 |
| Jain, D | 1 |
| Arava, S | 1 |
| Hadda, V | 1 |
| Mohan, A | 1 |
| Malik, P | 1 |
| Pandey, RM | 1 |
| Khilnani, GC | 1 |
| Guleria, R | 1 |
| Madan, K | 1 |
| Majumdar, JR | 1 |
| Vertosick, E | 1 |
| Long, M | 1 |
| Cansino, C | 1 |
| Assel, M | 1 |
| Twersky, R | 1 |
| Geist, MJP | 1 |
| Ziesenitz, VC | 1 |
| Bardenheuer, HJ | 2 |
| Burhenne, J | 1 |
| Skopp, G | 1 |
| Mikus, G | 1 |
| Shumaker, R | 1 |
| Ren, M | 1 |
| Aluri, J | 1 |
| Dutcus, CE | 1 |
| Rance, C | 1 |
| He, C | 1 |
| Maeda, S | 1 |
| Kato, I | 1 |
| Umeda, K | 1 |
| Hiramatsu, H | 1 |
| Takita, J | 1 |
| Adachi, S | 1 |
| Ogasawara, K | 1 |
| LoRusso, PM | 1 |
| Olszanski, AJ | 1 |
| Rixe, O | 1 |
| Xu, C | 1 |
| Yin, J | 1 |
| Palmisano, M | 1 |
| Krishna, G | 1 |
| Gamblin, V | 1 |
| Berry, V | 1 |
| Tresch-Bruneel, E | 1 |
| Reich, M | 1 |
| Da Silva, A | 1 |
| Villet, S | 1 |
| Penel, N | 1 |
| Prod'Homme, C | 1 |
| Monreal-Carrillo, E | 1 |
| Allende-Pérez, S | 1 |
| Hui, D | 2 |
| García-Salamanca, MF | 1 |
| Bruera, E | 3 |
| Verástegui, E | 1 |
| Tachibana, M | 1 |
| Papadopoulos, KP | 2 |
| Strickler, JH | 1 |
| Puzanov, I | 1 |
| Gajee, R | 1 |
| Wang, Y | 1 |
| Zahir, H | 1 |
| Koch, KM | 1 |
| Dees, EC | 2 |
| Coker, SA | 1 |
| Reddy, NJ | 1 |
| Gainer, SD | 1 |
| Arya, N | 1 |
| Beelen, AP | 1 |
| Beneton, A | 1 |
| Vallard, A | 1 |
| Brosse, C | 1 |
| Poenou, G | 1 |
| Pacaut, C | 1 |
| Magné, N | 1 |
| Morisson, S | 1 |
| Sauer, H | 1 |
| Graeber, S | 1 |
| Lieser, U | 1 |
| Foell, J | 1 |
| Bonilla-García, JL | 1 |
| Cortiñas-Sáenz, M | 1 |
| Pozo-Gavilán, ED | 1 |
| Prado, BL | 1 |
| Gomes, DBD | 1 |
| Usón Júnior, PLS | 1 |
| Taranto, P | 1 |
| França, MS | 1 |
| Eiger, D | 1 |
| Mariano, RC | 1 |
| Del Giglio, A | 1 |
| Ou, Y | 1 |
| Xu, Y | 1 |
| Gore, L | 1 |
| Harvey, RD | 1 |
| Mita, A | 1 |
| Wang, Z | 1 |
| Cutler, RE | 1 |
| Pinchasik, DE | 1 |
| Tsimberidou, AM | 2 |
| Serey, A | 1 |
| Tricou, C | 1 |
| Phan-Hoang, N | 1 |
| Legenne, M | 1 |
| Perceau-Chambard, É | 1 |
| Filbet, M | 1 |
| Won, YW | 1 |
| Chun, HS | 1 |
| Seo, M | 1 |
| Kim, RB | 1 |
| Kim, JH | 1 |
| Kang, JH | 2 |
| Giroud, M | 1 |
| Sellier, E | 1 |
| Laval, G | 1 |
| Mishra, SK | 1 |
| Lee, CW | 1 |
| Oh, SH | 1 |
| Ryu, JS | 1 |
| Bae, YS | 1 |
| Kim, HM | 1 |
| Mercadante, S | 1 |
| Porzio, G | 2 |
| Valle, A | 1 |
| Aielli, F | 2 |
| Casuccio, A | 1 |
| de Wit, D | 1 |
| Gelderblom, H | 2 |
| Sparreboom, A | 3 |
| den Hartigh, J | 2 |
| den Hollander, M | 2 |
| König-Quartel, JM | 2 |
| Hessing, T | 1 |
| Guchelaar, HJ | 2 |
| van Erp, NP | 2 |
| Seng, KY | 1 |
| Hee, KH | 1 |
| Soon, GH | 1 |
| Sapari, NS | 1 |
| Soong, R | 1 |
| Goh, BC | 3 |
| Lee, LS | 1 |
| Calvert, H | 1 |
| Twelves, C | 1 |
| Ranson, M | 1 |
| Plummer, R | 1 |
| Fettner, S | 1 |
| Pantze, M | 1 |
| Ling, J | 1 |
| Hamilton, M | 1 |
| Lum, BL | 1 |
| Rakhit, A | 1 |
| Korzeniewska-Eksterowicz, A | 1 |
| Przysło, Ł | 1 |
| Fendler, W | 1 |
| Stolarska, M | 1 |
| Młynarski, W | 1 |
| Calvo-Espinos, C | 1 |
| Ruiz de Gaona, E | 1 |
| Gonzalez, C | 1 |
| Ruiz de Galarreta, L | 1 |
| Lopez, C | 1 |
| Coutant, DE | 1 |
| Kulanthaivel, P | 1 |
| Turner, PK | 1 |
| Bell, RL | 1 |
| Baldwin, J | 1 |
| Wijayawardana, SR | 1 |
| Pitou, C | 1 |
| Hall, SD | 1 |
| Kaneishi, K | 1 |
| Kawabata, M | 1 |
| Hopprich, A | 1 |
| Günther, LD | 1 |
| Laufenberg-Feldmann, R | 1 |
| Reinholz, U | 1 |
| Weber, M | 1 |
| Plaschke, K | 1 |
| Petersen, KA | 1 |
| Frankenhauser, S | 1 |
| Weigand, MA | 1 |
| Kopitz, J | 1 |
| Fan, W | 1 |
| Yang, H | 1 |
| Sun, Y | 1 |
| Zhang, J | 1 |
| Li, G | 1 |
| Zheng, Y | 1 |
| Liu, Y | 1 |
| Franke, RM | 1 |
| Baker, SD | 4 |
| Mathijssen, RH | 3 |
| Schuetz, EG | 1 |
| Verna, L | 1 |
| Micolucci, G | 1 |
| Aloisi, P | 1 |
| Ficorella, C | 1 |
| Sanoff, HK | 1 |
| Davies, J | 1 |
| Walko, C | 1 |
| Buie, L | 1 |
| Chiu, WK | 1 |
| Ivanova, A | 1 |
| O'Neil, B | 1 |
| Stinchcombe, TE | 1 |
| Keller, K | 1 |
| Alonso-Babarro, A | 1 |
| Varela-Cerdeira, M | 1 |
| Torres-Vigil, I | 1 |
| Rodríguez-Barrientos, R | 1 |
| Navigante, AH | 2 |
| Castro, MA | 2 |
| Cerchietti, LC | 2 |
| Zandvliet, AS | 1 |
| Ploeger, BA | 1 |
| Chen, Z | 1 |
| Van Deijck, RH | 1 |
| Krijnsen, PJ | 1 |
| Hasselaar, JG | 1 |
| Verhagen, SC | 1 |
| Vissers, KC | 1 |
| Koopmans, RT | 1 |
| Lewis, N | 1 |
| Reid, T | 1 |
| Burris, H | 1 |
| Urban, P | 1 |
| Tan, EY | 1 |
| Anand, S | 1 |
| Uehara, C | 1 |
| Kurzrock, R | 1 |
| McGrath, EE | 1 |
| Warriner, D | 1 |
| Anderson, P | 1 |
| Radha Krishna, LK | 1 |
| Poulose, VJ | 1 |
| Goh, C | 1 |
| Gonçalves, F | 1 |
| Cordero, A | 1 |
| Almeida, A | 1 |
| Cruz, A | 1 |
| Rocha, C | 1 |
| Feio, M | 1 |
| Silva, P | 1 |
| Barbas, S | 1 |
| Neves, S | 1 |
| Infante, JR | 1 |
| Camidge, DR | 1 |
| Mileshkin, LR | 1 |
| Chen, EX | 1 |
| Hicks, RJ | 1 |
| Rischin, D | 1 |
| Fingert, H | 1 |
| Pierce, KJ | 1 |
| Xu, H | 1 |
| Roberts, WG | 1 |
| Shreeve, SM | 1 |
| Burris, HA | 1 |
| Siu, LL | 1 |
| Cheeti, S | 1 |
| Budha, NR | 1 |
| Rajan, S | 1 |
| Dresser, MJ | 1 |
| Jin, JY | 1 |
| Elens, L | 1 |
| Nieuweboer, A | 1 |
| Clarke, SJ | 1 |
| Charles, KA | 1 |
| de Graan, AJ | 1 |
| Haufroid, V | 1 |
| van Schaik, RH | 2 |
| Walker, SM | 1 |
| Goudas, LC | 1 |
| Cousins, MJ | 1 |
| Carr, DB | 1 |
| Zeng, WA | 1 |
| Wang, J | 1 |
| Lin, WQ | 1 |
| Tan, HY | 1 |
| Xu, MX | 1 |
| Crock, C | 1 |
| Olsson, C | 1 |
| Phillips, R | 1 |
| Chalkiadis, G | 1 |
| Sawyer, S | 1 |
| Ashley, D | 1 |
| Camilleri, S | 1 |
| Carlin, J | 1 |
| Monagle, P | 1 |
| Lee, HS | 2 |
| Fan, L | 1 |
| Khoo, YM | 1 |
| Wang, L | 1 |
| Lim, R | 1 |
| Ong, AB | 1 |
| Chua, C | 1 |
| Kain, ZN | 1 |
| Caldwell-Andrews, AA | 1 |
| Wang, SM | 1 |
| Krivutza, DM | 1 |
| Weinberg, ME | 1 |
| Mayes, LC | 1 |
| Tei, Y | 1 |
| Wong, M | 2 |
| Balleine, RL | 2 |
| Collins, M | 2 |
| Liddle, C | 1 |
| Clarke, CL | 2 |
| Gurney, H | 2 |
| Cameron, D | 1 |
| Bridge, D | 1 |
| Blitz-Lindeque, J | 1 |
| Ozdemir, D | 1 |
| Kayserili, E | 1 |
| Arslanoglu, S | 1 |
| Gulez, P | 1 |
| Vergin, C | 1 |
| Ueoka, H | 1 |
| Takeyama, H | 1 |
| Murakami, T | 1 |
| Mandalà, M | 1 |
| Cremonesi, M | 1 |
| Rocca, A | 1 |
| Cazzaniga, M | 1 |
| Ferretti, G | 1 |
| Di Cosimo, S | 1 |
| Ghilardi, M | 1 |
| Cabiddu, M | 1 |
| Barni, S | 1 |
| Iannalfi, A | 1 |
| Bernini, G | 1 |
| Caprilli, S | 1 |
| Lippi, A | 1 |
| Tucci, F | 1 |
| Messeri, A | 1 |
| Gottschling, S | 1 |
| Meyer, S | 1 |
| Krenn, T | 1 |
| Reinhard, H | 1 |
| Lothschuetz, D | 1 |
| Nunold, H | 1 |
| Graf, N | 1 |
| Lepper, ER | 1 |
| Permenter, M | 1 |
| Ries, N | 1 |
| Schenk, PW | 1 |
| Price, DK | 1 |
| Ahn, D | 1 |
| Smith, NF | 1 |
| Cusatis, G | 1 |
| Ingersoll, RG | 1 |
| Bates, SE | 1 |
| Verweij, J | 1 |
| Figg, WD | 1 |
| Lutteral, MA | 1 |
| Cabalar, ME | 1 |
| Førde, R | 1 |
| Kongsgaard, U | 1 |
| Aasland, OG | 1 |
| Blair, EY | 1 |
| McLachlan, AJ | 1 |
| Ackland, SP | 1 |
| Garg, MB | 1 |
| Evans, S | 1 |
| Farlow, D | 1 |
| Rivory, LP | 1 |
| Hoskins, JM | 1 |
| Mann, GJ | 1 |
| Amesbury, BD | 1 |
| Alexandre, J | 1 |
| Rey, E | 1 |
| Girre, V | 1 |
| Grabar, S | 1 |
| Tran, A | 1 |
| Montheil, V | 1 |
| Rabillon, F | 1 |
| Dieras, V | 1 |
| Jullien, V | 1 |
| Hérait, P | 1 |
| Pons, G | 1 |
| Treluyer, JM | 1 |
| Goldwasser, F | 1 |
| Messersmith, WA | 1 |
| Rudek, MA | 1 |
| Zhao, M | 1 |
| Collins, C | 1 |
| Colevas, AD | 1 |
| Donehower, RC | 1 |
| Carducci, MA | 1 |
| Wolff, AC | 1 |
| Sironi, O | 1 |
| Sbanotto, A | 1 |
| Banfi, MG | 1 |
| Beltrami, C | 1 |
| Yong, WP | 1 |
| Wang, LZ | 1 |
| Tham, LS | 1 |
| Wong, CI | 1 |
| Lee, SC | 1 |
| Soo, R | 1 |
| Sukri, N | 1 |
| Bhatnagar, S | 1 |
| Mishra, S | 1 |
| Gupta, M | 1 |
| Srikanti, M | 1 |
| Mondol, A | 1 |
| Diwedi, A | 1 |
| Rosland, JH | 1 |
| Saunes, TK | 1 |
| Bull, AN | 1 |
| Matsuo, N | 1 |
| Kushida, A | 1 |
| Inada, T | 1 |
| Shingu, K | 1 |
| Elsayem, A | 1 |
| Curry Iii, E | 1 |
| Boohene, J | 1 |
| Munsell, MF | 1 |
| Calderon, B | 1 |
| Hung, F | 1 |
| González-Arrieta, ML | 1 |
| Juárez Melendez, J | 1 |
| Silva Hernández, J | 1 |
| Galindo Fabian, A | 1 |
| Labastida, S | 1 |
| Campos, A | 1 |
| Jiménez Villarruel, M | 1 |
| Bleasel, MD | 1 |
| Peterson, GM | 1 |
| Dunne, PF | 1 |
| Potanovich, LM | 1 |
| Pisters, KM | 1 |
| Kris, MG | 1 |
| Tyson, LB | 1 |
| Clark, RA | 1 |
| Baltzer, L | 1 |
| Gralla, RJ | 1 |
| Krossnes, BK | 1 |
| Mella, O | 1 |
| Dahl, O | 1 |
| Oneschuk, D | 1 |
| Ljungman, G | 1 |
| Kreuger, A | 1 |
| Andréasson, S | 1 |
| Gordh, T | 1 |
| Sörensen, S | 1 |
| Verhagen, EH | 1 |
| Eliel, MR | 1 |
| de Graeff, A | 1 |
| Teunissen, SC | 1 |
| Lauretti, GR | 1 |
| Gomes, JM | 1 |
| Reis, MP | 1 |
| Pereira, NL | 1 |
| Pellier, I | 1 |
| Monrigal, JP | 1 |
| Le Moine, P | 1 |
| Rod, B | 1 |
| Rialland, X | 1 |
| Granry, JC | 1 |
| Negro, S | 1 |
| Azuara, ML | 1 |
| Sánchez, Y | 1 |
| Reyes, R | 1 |
| Barcia, E | 1 |
| Sandler, ES | 1 |
| Weyman, C | 2 |
| Conner, K | 2 |
| Reilly, K | 2 |
| Dickson, N | 2 |
| Luzins, J | 2 |
| McGorray, S | 1 |
| Sandler, E | 1 |
| Burke, AL | 1 |
| Diamond, PL | 1 |
| Hulbert, J | 1 |
| Yeatman, J | 1 |
| Farr, EA | 1 |
| Sievers, TD | 1 |
| Yee, JD | 1 |
| Foley, ME | 1 |
| Blanding, PJ | 1 |
| Berde, CB | 1 |
| Bottomley, DM | 1 |
| Hanks, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors[NCT02686164] | Phase 1 | 51 participants (Actual) | Interventional | 2016-04-18 | Completed | ||
| Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial[NCT04532606] | Phase 4 | 1,128 participants (Anticipated) | Interventional | 2021-02-05 | Recruiting | ||
| Use of Handheld Audiovisual Devices to Treat Pediatric Preoperative Anxiety: A Randomized Control Trial.[NCT02286674] | 200 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Phase I Study of Continuous Weekly Dosing of Dimethyl Benzoylphenylurea (BPU) in Patients With Solid Tumors Not Responding to Conventional Therapy[NCT00016354] | Phase 1 | 19 participants (Actual) | Interventional | 2001-03-31 | Completed | ||
| The Effects of Propofol Based Intravenous vs Sevoflurane Inhalation Anaesthesia on Inflammation and Circulating Tumor Cells in Paediatric Tumor Surgery - a Pilot Study[NCT04475705] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-01-11 | Recruiting | ||
| A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer[NCT01975064] | Phase 4 | 5,774 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02686164)
Timeframe: Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)
| Intervention | hour*nanograms per milliliter (h*ng/mL) (Mean) | |
|---|---|---|
| Midazolam | 1'-hydroxymidazolam | |
| Cycle 1 Day -3: Midazolam | 92.5 | 38.5 |
| Cycle 1 Day 1: Lenvatinib + Midazolam | 89.7 | 48.6 |
| Cycle 1 Day 14: Lenvatinib + Midazolam | 117 | 41.3 |
(NCT02686164)
Timeframe: Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)
| Intervention | nanogram per milliliter (ng/mL) (Mean) | |
|---|---|---|
| Midazolam | 1'-hydroxy midazolam | |
| Cycle 1 Day -3: Midazolam | 26.5 | 11.0 |
| Cycle 1 Day 1: Lenvatinib + Midazolam | 24.8 | 12.7 |
| Cycle 1 Day 14: Lenvatinib + Midazolam | 28.3 | 10.7 |
(NCT02686164)
Timeframe: First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years)
| Intervention | participants (Number) | |
|---|---|---|
| TEAEs | SAEs | |
| Midazolam + Lenvatinib | 30 | 10 |
Toxicity was assessed weekly during the first 2 cycles, and monthly thereafter, using the National Cancer Institute Common Toxicity Criteria (NCI CTCv2). Dose limiting toxicity (DLT) was defined as dose delays >2 weeks, grade 4 haematologic toxicity (except grade 4 neutropenia lasting <5 days), or grade 3 nonhaematologic toxicity. The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience a dose-limiting toxicity. (NCT00016354)
Timeframe: 4 weeks (1 course of treatment for each subject)
| Intervention | milligrams (mg) (Number) |
|---|---|
| Benzoylphenylurea | 150 |
6 reviews available for midazolam and Neoplasms
| Article | Year |
|---|---|
Palliative Sedation at Home: A Scoping Review.
Topics: Adult; Child; Death; Dyspnea; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Pain; Palliativ | 2023 |
Palliative Sedation at Home: A Scoping Review.
Topics: Adult; Child; Death; Dyspnea; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Pain; Palliativ | 2023 |
Systematic review and meta-analysis of the efficacy of benzodiazepines for dyspnea in patients with cancer.
Topics: Analgesics, Opioid; Benzodiazepines; Dyspnea; Humans; Midazolam; Morphine; Neoplasms; Sleepiness | 2023 |
Systematic review and meta-analysis of the efficacy of benzodiazepines for dyspnea in patients with cancer.
Topics: Analgesics, Opioid; Benzodiazepines; Dyspnea; Humans; Midazolam; Morphine; Neoplasms; Sleepiness | 2023 |
Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
Topics: Acute-Phase Proteins; Cytochrome P-450 Enzyme System; Cytokines; Drug Interactions; Humans; Imidazol | 2015 |
Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
Topics: Acute-Phase Proteins; Cytochrome P-450 Enzyme System; Cytokines; Drug Interactions; Humans; Imidazol | 2015 |
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Topics: Breath Tests; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule | 2008 |
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Topics: Breath Tests; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule | 2008 |
Combination spinal analgesic chemotherapy: a systematic review.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Anesthetics, Local; Antineoplastic Agents; Cholineste | 2002 |
Combination spinal analgesic chemotherapy: a systematic review.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Anesthetics, Local; Antineoplastic Agents; Cholineste | 2002 |
[Sedation in the terminal phase of life].
Topics: Adult; Anti-Anxiety Agents; Conscious Sedation; Delirium; Euthanasia, Passive; Female; Humans; Hypno | 1999 |
[Sedation in the terminal phase of life].
Topics: Adult; Anti-Anxiety Agents; Conscious Sedation; Delirium; Euthanasia, Passive; Female; Humans; Hypno | 1999 |
33 trials available for midazolam and Neoplasms
| Article | Year |
|---|---|
Effect of Combined Epidural Morphine and Midazolam on Postoperative Pain in Patients Undergoing Major Abdominal Cancer Surgery.
Topics: Analgesia, Epidural; Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Double-Blind M | 2022 |
Effect of Combined Epidural Morphine and Midazolam on Postoperative Pain in Patients Undergoing Major Abdominal Cancer Surgery.
Topics: Analgesia, Epidural; Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Double-Blind M | 2022 |
The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial.
Topics: Child; Cross-Over Studies; Fentanyl; Humans; Hypnotics and Sedatives; Ketamine; Midazolam; Neoplasms | 2022 |
The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial.
Topics: Child; Cross-Over Studies; Fentanyl; Humans; Hypnotics and Sedatives; Ketamine; Midazolam; Neoplasms | 2022 |
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochr | 2023 |
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochr | 2023 |
Rigid Mini-Thoracoscopy Versus Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusion: The MINT Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Biopsy; Exudates and Transudates; Female; Fentanyl; Humans; Hypnotics and | 2020 |
Rigid Mini-Thoracoscopy Versus Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusion: The MINT Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Biopsy; Exudates and Transudates; Female; Fentanyl; Humans; Hypnotics and | 2020 |
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Dru | 2020 |
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Dru | 2020 |
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross | 2020 |
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross | 2020 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B | 2018 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B | 2018 |
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhi | 2019 |
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhi | 2019 |
CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Topics: Adult; Aged; Anti-Anxiety Agents; Asian People; Bilirubin; Body Weight; Creatinine; Cytochrome P-450 | 2014 |
CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Topics: Adult; Aged; Anti-Anxiety Agents; Asian People; Bilirubin; Body Weight; Creatinine; Cytochrome P-450 | 2014 |
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotin | 2014 |
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotin | 2014 |
Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
Topics: Adult; Antidepressive Agents; Depression; Female; Humans; Ketamine; Male; Midazolam; Middle Aged; Ne | 2017 |
Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
Topics: Adult; Antidepressive Agents; Depression; Female; Humans; Ketamine; Male; Midazolam; Middle Aged; Ne | 2017 |
Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 | 2011 |
Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 | 2011 |
Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Anxiety Agents; Drug Administration Schedul | 2010 |
Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Anxiety Agents; Drug Administration Schedul | 2010 |
Marginal increase of sunitinib exposure by grapefruit juice.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus par | 2011 |
Marginal increase of sunitinib exposure by grapefruit juice.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus par | 2011 |
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2011 |
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2011 |
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Canada; Cytochrome P-450 CYP3A; Cy | 2012 |
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Canada; Cytochrome P-450 CYP3A; Cy | 2012 |
[Effects of midazolam premedication on induction doses of propofol and hemodynamic changes during tumor patient induction].
Topics: Adjuvants, Anesthesia; Adult; Aged; Anti-Anxiety Agents; Female; Hemodynamics; Humans; Hypnotics and | 2002 |
[Effects of midazolam premedication on induction doses of propofol and hemodynamic changes during tumor patient induction].
Topics: Adjuvants, Anesthesia; Adult; Aged; Anti-Anxiety Agents; Female; Hemodynamics; Humans; Hypnotics and | 2002 |
Ketamine and midazolam for invasive procedures in children with malignancy: a comparison of routes of intravenous, oral, and rectal administration.
Topics: Administration, Oral; Administration, Rectal; Anesthesia Recovery Period; Anesthetics, Combined; Ane | 2004 |
Ketamine and midazolam for invasive procedures in children with malignancy: a comparison of routes of intravenous, oral, and rectal administration.
Topics: Administration, Oral; Administration, Rectal; Anesthesia Recovery Period; Anesthetics, Combined; Ane | 2004 |
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Graniset | 2005 |
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Graniset | 2005 |
Propofol versus midazolam/ketamine for procedural sedation in pediatric oncology.
Topics: Adolescent; Anesthetics, Dissociative; Child; Child, Preschool; Conscious Sedation; Humans; Hypnotic | 2005 |
Propofol versus midazolam/ketamine for procedural sedation in pediatric oncology.
Topics: Adolescent; Anesthetics, Dissociative; Child; Child, Preschool; Conscious Sedation; Humans; Hypnotic | 2005 |
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Topics: Adult; Aged; Alleles; Area Under Curve; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP3A; C | 2005 |
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Topics: Adult; Aged; Alleles; Area Under Curve; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP3A; C | 2005 |
Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.
Topics: Adult; Aged; Analgesics, Opioid; Drug Therapy, Combination; Dyspnea; Female; Humans; Hypnotics and S | 2006 |
Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.
Topics: Adult; Aged; Analgesics, Opioid; Drug Therapy, Combination; Dyspnea; Female; Humans; Hypnotics and S | 2006 |
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female | 2007 |
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female | 2007 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
Efficacy and safety of a mixture of ketamine, midazolam and atropine for procedural sedation in paediatric oncology: a randomised study of oral versus intramuscular route.
Topics: Administration, Oral; Anesthetics, Combined; Atropine; Child; Child, Preschool; Humans; Hypnotics an | 2008 |
Efficacy and safety of a mixture of ketamine, midazolam and atropine for procedural sedation in paediatric oncology: a randomised study of oral versus intramuscular route.
Topics: Administration, Oral; Anesthetics, Combined; Atropine; Child; Child, Preschool; Humans; Hypnotics an | 2008 |
Total intravenous anesthesia with propofol vs. propofol/midazolam in oncology patients.
Topics: Adult; Aged; Anesthesia, Intravenous; Drug Interactions; Female; Humans; Male; Midazolam; Middle Age | 1995 |
Total intravenous anesthesia with propofol vs. propofol/midazolam in oncology patients.
Topics: Adult; Aged; Anesthesia, Intravenous; Drug Interactions; Female; Humans; Male; Midazolam; Middle Age | 1995 |
Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care.
Topics: Age Factors; Aged; Aged, 80 and over; Chromatography, Gas; Drug Monitoring; Female; Humans; Infusion | 1994 |
Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care.
Topics: Age Factors; Aged; Aged, 80 and over; Chromatography, Gas; Drug Monitoring; Female; Humans; Infusion | 1994 |
Midazolam in patients receiving anticancer chemotherapy and antiemetics.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Com | 1993 |
Midazolam in patients receiving anticancer chemotherapy and antiemetics.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Com | 1993 |
Midazolam nasal spray reduces procedural anxiety in children.
Topics: Administration, Intranasal; Adolescent; Aerosols; Anti-Anxiety Agents; Anxiety; Catheterization, Cen | 2000 |
Midazolam nasal spray reduces procedural anxiety in children.
Topics: Administration, Intranasal; Adolescent; Aerosols; Anti-Anxiety Agents; Anxiety; Catheterization, Cen | 2000 |
Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy.
Topics: Adult; Aged; Analgesia, Epidural; Double-Blind Method; Drug Synergism; Female; Humans; Ketamine; Mal | 1999 |
Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy.
Topics: Adult; Aged; Analgesia, Epidural; Double-Blind Method; Drug Synergism; Female; Humans; Ketamine; Mal | 1999 |
Midazolam versus fentanyl as premedication for painful procedures in children with cancer.
Topics: Adolescent; Anxiety; Bone Marrow Examination; Child; Child, Preschool; Conscious Sedation; Double-Bl | 1992 |
Midazolam versus fentanyl as premedication for painful procedures in children with cancer.
Topics: Adolescent; Anxiety; Bone Marrow Examination; Child; Child, Preschool; Conscious Sedation; Double-Bl | 1992 |
Intravenous midazolam versus fentanyl as premedication for painful procedures in pediatric oncology patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Double-Blind Method; Fentanyl; Humans; Midazolam; Neopla | 1991 |
Intravenous midazolam versus fentanyl as premedication for painful procedures in pediatric oncology patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Double-Blind Method; Fentanyl; Humans; Midazolam; Neopla | 1991 |
59 other studies available for midazolam and Neoplasms
| Article | Year |
|---|---|
SAR156497, an exquisitely selective inhibitor of aurora kinases.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; B | 2015 |
SAR156497, an exquisitely selective inhibitor of aurora kinases.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; B | 2015 |
Involvement of the Parathyroid Hormone-Related Protein on Changes in the CYP3A Expression in Cancer Cachexia.
Topics: Animals; Cachexia; Caco-2 Cells; Cytochrome P-450 CYP3A; Hep G2 Cells; Humans; Liver; Male; Midazola | 2021 |
Involvement of the Parathyroid Hormone-Related Protein on Changes in the CYP3A Expression in Cancer Cachexia.
Topics: Animals; Cachexia; Caco-2 Cells; Cytochrome P-450 CYP3A; Hep G2 Cells; Humans; Liver; Male; Midazola | 2021 |
The quality of palliative sedation in end-stage disease: audit from a department of oncology and haematology.
Topics: Conscious Sedation; Deep Sedation; Hematology; Humans; Hypnotics and Sedatives; Medical Oncology; Mi | 2022 |
The quality of palliative sedation in end-stage disease: audit from a department of oncology and haematology.
Topics: Conscious Sedation; Deep Sedation; Hematology; Humans; Hypnotics and Sedatives; Medical Oncology; Mi | 2022 |
Family experience of palliative sedation therapy: proportional vs. continuous deep sedation.
Topics: Deep Sedation; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Palliative Care; Surveys and Q | 2022 |
Family experience of palliative sedation therapy: proportional vs. continuous deep sedation.
Topics: Deep Sedation; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Palliative Care; Surveys and Q | 2022 |
Sedation in specialized palliative care: A cross-sectional study.
Topics: Cross-Sectional Studies; Deep Sedation; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Palli | 2022 |
Sedation in specialized palliative care: A cross-sectional study.
Topics: Cross-Sectional Studies; Deep Sedation; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Palli | 2022 |
Immune cells are affected by midazolam through the translocator protein in tumour immune microenvironments.
Topics: Humans; Midazolam; Neoplasms; Receptors, GABA-A; Tumor Microenvironment | 2022 |
Immune cells are affected by midazolam through the translocator protein in tumour immune microenvironments.
Topics: Humans; Midazolam; Neoplasms; Receptors, GABA-A; Tumor Microenvironment | 2022 |
The clinical practice of palliative sedation in patients dying from COVID-19: a retrospective chart review.
Topics: Adult; COVID-19; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Palliative Care; Pandemics; | 2023 |
The clinical practice of palliative sedation in patients dying from COVID-19: a retrospective chart review.
Topics: Adult; COVID-19; Humans; Hypnotics and Sedatives; Midazolam; Neoplasms; Palliative Care; Pandemics; | 2023 |
Effects of Midazolam on Postoperative Nausea and Vomiting and Discharge Times in Outpatients Undergoing Cancer-Related Surgery.
Topics: Adult; Aged; Anesthesia, General; Cohort Studies; Female; Humans; Hypnotics and Sedatives; Laparosco | 2019 |
Effects of Midazolam on Postoperative Nausea and Vomiting and Discharge Times in Outpatients Undergoing Cancer-Related Surgery.
Topics: Adult; Aged; Anesthesia, General; Cohort Studies; Female; Humans; Hypnotics and Sedatives; Laparosco | 2019 |
Continuous deep sedation at the end of life in children with cancer: experience at a single center in Japan.
Topics: Activities of Daily Living; Adolescent; Child; Child, Preschool; Deep Sedation; Family; Humans; Hypn | 2020 |
Continuous deep sedation at the end of life in children with cancer: experience at a single center in Japan.
Topics: Activities of Daily Living; Adolescent; Child; Child, Preschool; Deep Sedation; Family; Humans; Hypn | 2020 |
Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control.
Topics: Adult; Aged; Aged, 80 and over; Female; France; Humans; Hypnotics and Sedatives; Male; Midazolam; Mi | 2020 |
Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control.
Topics: Adult; Aged; Aged, 80 and over; Female; France; Humans; Hypnotics and Sedatives; Male; Midazolam; Mi | 2020 |
Bispectral Index monitoring in cancer patients undergoing palliative sedation: a preliminary report.
Topics: Adult; Aged; Awareness; Cancer Pain; Conscious Sedation; Consciousness; Delirium; Electroencephalogr | 2017 |
Bispectral Index monitoring in cancer patients undergoing palliative sedation: a preliminary report.
Topics: Adult; Aged; Awareness; Cancer Pain; Conscious Sedation; Consciousness; Delirium; Electroencephalogr | 2017 |
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Lapa | 2017 |
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Lapa | 2017 |
[Towards a better use of midazolam in end of life: A survey in a department of medical oncology].
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Checklist; Clinical Decision-Making; Female; France; Guidel | 2017 |
[Towards a better use of midazolam in end of life: A survey in a department of medical oncology].
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Checklist; Clinical Decision-Making; Female; France; Guidel | 2017 |
Bone marrow aspirations in oncological patients: experience from an in-house standard in paediatrics.
Topics: Bone Marrow Examination; Child; Conscious Sedation; Humans; Midazolam; Neoplasms; Pain Measurement; | 2019 |
Bone marrow aspirations in oncological patients: experience from an in-house standard in paediatrics.
Topics: Bone Marrow Examination; Child; Conscious Sedation; Humans; Midazolam; Neoplasms; Pain Measurement; | 2019 |
Opioids and immunosupression in oncological postoperative patients.
Topics: Aged; Analgesics, Opioid; Cross Infection; Female; Humans; Immunosuppressive Agents; Male; Midazolam | 2017 |
Opioids and immunosupression in oncological postoperative patients.
Topics: Aged; Analgesics, Opioid; Cross Infection; Female; Humans; Immunosuppressive Agents; Male; Midazolam | 2017 |
Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Deep Sedation; Delirium; Dyspnea; Female; Humans; Hyp | 2018 |
Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Deep Sedation; Delirium; Dyspnea; Female; Humans; Hyp | 2018 |
Deep continuous patient-requested sedation until death: a multicentric study.
Topics: Adolescent; Conscious Sedation; Deep Sedation; France; Hospice and Palliative Care Nursing; Humans; | 2023 |
Deep continuous patient-requested sedation until death: a multicentric study.
Topics: Adolescent; Conscious Sedation; Deep Sedation; France; Hospice and Palliative Care Nursing; Humans; | 2023 |
Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study.
Topics: Aged; Conscious Sedation; Deep Sedation; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Pa | 2019 |
Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study.
Topics: Aged; Conscious Sedation; Deep Sedation; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Pa | 2019 |
[Use of midazolam in hospitalized patients: analysis of medical practice].
Topics: Aged; Aged, 80 and over; Anxiety; Female; France; Hospitalization; Humans; Hypnotics and Sedatives; | 2013 |
[Use of midazolam in hospitalized patients: analysis of medical practice].
Topics: Aged; Aged, 80 and over; Anxiety; Female; France; Hospitalization; Humans; Hypnotics and Sedatives; | 2013 |
Midazolam induces cellular apoptosis in human cancer cells and inhibits tumor growth in xenograft mice.
Topics: Adjuvants, Anesthesia; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Prolife | 2013 |
Midazolam induces cellular apoptosis in human cancer cells and inhibits tumor growth in xenograft mice.
Topics: Adjuvants, Anesthesia; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Prolife | 2013 |
Palliative sedation in patients with advanced cancer followed at home: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Delirium; Dyspnea; Family; Feasibility Studies; Female; Home Care Se | 2014 |
Palliative sedation in patients with advanced cancer followed at home: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Delirium; Dyspnea; Family; Feasibility Studies; Female; Home Care Se | 2014 |
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Female; Humans; Indole | 2014 |
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Female; Humans; Indole | 2014 |
Palliative sedation at home for terminally ill children with cancer.
Topics: Adolescent; Age Factors; Analgesics, Opioid; Child; Child, Preschool; Female; Home Care Services; Hu | 2014 |
Palliative sedation at home for terminally ill children with cancer.
Topics: Adolescent; Age Factors; Analgesics, Opioid; Child; Child, Preschool; Female; Home Care Services; Hu | 2014 |
Palliative sedation for cancer patients included in a home care program: a retrospective study.
Topics: Conscious Sedation; Cross-Sectional Studies; Female; Home Care Services; Humans; Male; Methotrimepra | 2015 |
Palliative sedation for cancer patients included in a home care program: a retrospective study.
Topics: Conscious Sedation; Cross-Sectional Studies; Female; Home Care Services; Humans; Male; Methotrimepra | 2015 |
Single-Dose Subcutaneous Benzodiazepines for Insomnia in Patients With Advanced Cancer.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Female; Flunitrazepam; Humans; Hypnotics and | 2015 |
Single-Dose Subcutaneous Benzodiazepines for Insomnia in Patients With Advanced Cancer.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Female; Flunitrazepam; Humans; Hypnotics and | 2015 |
[Palliative sedation at a university palliative care unit--a descriptive analysis].
Topics: Academic Medical Centers; Analgesics, Opioid; Conscious Sedation; Deep Sedation; Humans; Hypnotics a | 2016 |
[Palliative sedation at a university palliative care unit--a descriptive analysis].
Topics: Academic Medical Centers; Analgesics, Opioid; Conscious Sedation; Deep Sedation; Humans; Hypnotics a | 2016 |
The Impact of Plasma Cholinergic Enzyme Activity and Other Risk Factors for the Development of Delirium in Patients Receiving Palliative Care.
Topics: Aged; Biomarkers; Cholinergic Antagonists; Cholinesterases; Delirium; Female; Humans; Karnofsky Perf | 2016 |
The Impact of Plasma Cholinergic Enzyme Activity and Other Risk Factors for the Development of Delirium in Patients Receiving Palliative Care.
Topics: Aged; Biomarkers; Cholinergic Antagonists; Cholinesterases; Delirium; Female; Humans; Karnofsky Perf | 2016 |
Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Deep Sedation; Feasibility Studies; Female; Home Care Services; Huma | 2010 |
Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Deep Sedation; Feasibility Studies; Female; Home Care Services; Huma | 2010 |
At-home palliative sedation for end-of-life cancer patients.
Topics: Aged; Checklist; Conscious Sedation; Female; Home Care Services; Humans; Hypnotics and Sedatives; Ma | 2010 |
At-home palliative sedation for end-of-life cancer patients.
Topics: Aged; Checklist; Conscious Sedation; Female; Home Care Services; Humans; Hypnotics and Sedatives; Ma | 2010 |
The practice of continuous palliative sedation in elderly patients: a nationwide explorative study among Dutch nursing home physicians.
Topics: Adult; Aged; Clinical Competence; Conscious Sedation; Dementia; Dose-Response Relationship, Drug; Fe | 2010 |
The practice of continuous palliative sedation in elderly patients: a nationwide explorative study among Dutch nursing home physicians.
Topics: Adult; Aged; Clinical Competence; Conscious Sedation; Dementia; Dose-Response Relationship, Drug; Fe | 2010 |
The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Bronchial Diseases; Bronchoscopy; Carcinoma; Carcinoma, Non-Small-Ce | 2012 |
The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Bronchial Diseases; Bronchoscopy; Carcinoma; Carcinoma, Non-Small-Ce | 2012 |
The use of midazolam and haloperidol in cancer patients at the end of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Haloperidol; Humans; Hypnoti | 2012 |
The use of midazolam and haloperidol in cancer patients at the end of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Haloperidol; Humans; Hypnoti | 2012 |
A survey of the sedation practice of Portuguese palliative care teams.
Topics: Adult; Aged; Aged, 80 and over; Conscious Sedation; Deep Sedation; Delirium; Female; Humans; Hypnoti | 2012 |
A survey of the sedation practice of Portuguese palliative care teams.
Topics: Adult; Aged; Aged, 80 and over; Conscious Sedation; Deep Sedation; Delirium; Female; Humans; Hypnoti | 2012 |
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Body Mass Index; Body Size; Body Weight; Female | 2013 |
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Body Mass Index; Body Size; Body Weight; Female | 2013 |
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Topics: Breath Tests; Cytochrome P-450 CYP3A; DNA; Erythromycin; Female; Humans; Injections, Intravenous; In | 2013 |
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Topics: Breath Tests; Cytochrome P-450 CYP3A; DNA; Erythromycin; Female; Humans; Injections, Intravenous; In | 2013 |
General anaesthesia or conscious sedation for painful procedures in childhood cancer: the family's perspective.
Topics: Adolescent; Anesthesia, General; Anesthesia, Inhalation; Anesthetics, Intravenous; Biopsy, Needle; B | 2003 |
General anaesthesia or conscious sedation for painful procedures in childhood cancer: the family's perspective.
Topics: Adolescent; Anesthesia, General; Anesthesia, Inhalation; Anesthetics, Intravenous; Biopsy, Needle; B | 2003 |
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asia; Chromatography, High Pressure Liquid; | 2003 |
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asia; Chromatography, High Pressure Liquid; | 2003 |
Parental intervention choices for children undergoing repeated surgeries.
Topics: Anesthesia; Anxiety; Anxiety, Separation; Child; Child, Preschool; Chronic Disease; Female; Humans; | 2003 |
Parental intervention choices for children undergoing repeated surgeries.
Topics: Anesthesia; Anxiety; Anxiety, Separation; Child; Child, Preschool; Chronic Disease; Female; Humans; | 2003 |
Correlation of the dose of midazolam for symptom control with administration periods: the possibility of tolerance.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Admini | 2003 |
Correlation of the dose of midazolam for symptom control with administration periods: the possibility of tolerance.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Admini | 2003 |
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Australia; Cytochrome P | 2004 |
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Australia; Cytochrome P | 2004 |
Use of sedation to relieve refractory symptoms in dying patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Communication; Conscious Sedatio | 2004 |
Use of sedation to relieve refractory symptoms in dying patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Communication; Conscious Sedatio | 2004 |
Sedation for terminally ill patients with cancer with uncontrollable physical distress.
Topics: Adult; Aged; Aged, 80 and over; Conscious Sedation; Consciousness; Dose-Response Relationship, Drug; | 2005 |
Sedation for terminally ill patients with cancer with uncontrollable physical distress.
Topics: Adult; Aged; Aged, 80 and over; Conscious Sedation; Consciousness; Dose-Response Relationship, Drug; | 2005 |
Painful procedures in children with cancer: comparison of moderate sedation and general anesthesia for lumbar puncture and bone marrow aspiration.
Topics: Analgesics, Non-Narcotic; Anesthesia, General; Bone Marrow Examination; Child; Child, Preschool; Con | 2005 |
Painful procedures in children with cancer: comparison of moderate sedation and general anesthesia for lumbar puncture and bone marrow aspiration.
Topics: Analgesics, Non-Narcotic; Anesthesia, General; Bone Marrow Examination; Child; Child, Preschool; Con | 2005 |
[Palliative sedation to the dying].
Topics: Adult; Aged; Analgesics, Opioid; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Ag | 2006 |
[Palliative sedation to the dying].
Topics: Adult; Aged; Analgesics, Opioid; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Ag | 2006 |
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, | 2006 |
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, | 2006 |
High-dose subcutaneous midazolam infusions in palliative care.
Topics: Humans; Hypnotics and Sedatives; Infusions, Intravenous; Injections, Subcutaneous; Midazolam; Neopla | 1992 |
High-dose subcutaneous midazolam infusions in palliative care.
Topics: Humans; Hypnotics and Sedatives; Infusions, Intravenous; Injections, Subcutaneous; Midazolam; Neopla | 1992 |
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Docetaxel; Female; Ferritins; | 2007 |
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Docetaxel; Female; Ferritins; | 2007 |
Midazolam as adjunct therapy to morphine to relieve dyspnea?
Topics: Analgesics, Opioid; Drug Therapy, Combination; Dyspnea; Humans; Hypnotics and Sedatives; Midazolam; | 2007 |
Midazolam as adjunct therapy to morphine to relieve dyspnea?
Topics: Analgesics, Opioid; Drug Therapy, Combination; Dyspnea; Humans; Hypnotics and Sedatives; Midazolam; | 2007 |
[Treatment of intolerable sufferings in a hospice unit].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Hospices; Humans; Hypnotics and Sedative | 2007 |
[Treatment of intolerable sufferings in a hospice unit].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Hospices; Humans; Hypnotics and Sedative | 2007 |
Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study.
Topics: Aged; Anti-Anxiety Agents; Cost-Benefit Analysis; Female; Flunitrazepam; Humans; Japan; Male; Medica | 2007 |
Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study.
Topics: Aged; Anti-Anxiety Agents; Cost-Benefit Analysis; Female; Flunitrazepam; Humans; Japan; Male; Medica | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Enhancement of antitumor immunity after propofol treatment in mice.
Topics: Adjuvants, Immunologic; Animals; Blood Proteins; Body Weight; Cell Count; Cell Line, Tumor; Fat Emul | 2007 |
Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chlorpromazine; Female; Humans; Hypnotics an | 2009 |
Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chlorpromazine; Female; Humans; Hypnotics an | 2009 |
Use of the vasodilator sodium nitroprusside during local hyperthermia: effects on tumor temperature and tumor response in a rat tumor model.
Topics: Animals; Blood Pressure; Body Temperature; Butyrophenones; Fentanyl; Glioma; Hyperthermia, Induced; | 1996 |
Use of the vasodilator sodium nitroprusside during local hyperthermia: effects on tumor temperature and tumor response in a rat tumor model.
Topics: Animals; Blood Pressure; Body Temperature; Butyrophenones; Fentanyl; Glioma; Hyperthermia, Induced; | 1996 |
Subcutaneous midazolam for acute hemorrhage in patients with advanced cancer.
Topics: Acute Disease; Hemorrhage; Humans; Hypnotics and Sedatives; Infusions, Parenteral; Midazolam; Neopla | 1998 |
Subcutaneous midazolam for acute hemorrhage in patients with advanced cancer.
Topics: Acute Disease; Hemorrhage; Humans; Hypnotics and Sedatives; Infusions, Parenteral; Midazolam; Neopla | 1998 |
Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study.
Topics: Adolescent; Analgesics; Biopsy; Biopsy, Needle; Blood Pressure; Catheterization, Central Venous; Chi | 1999 |
Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study.
Topics: Adolescent; Analgesics; Biopsy; Biopsy, Needle; Blood Pressure; Catheterization, Central Venous; Chi | 1999 |
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Butylscopolammonium Bromide; Dexamethasone; Drug Evaluat | 2002 |
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Butylscopolammonium Bromide; Dexamethasone; Drug Evaluat | 2002 |
Terminal restlessness--its management and the role of midazolam.
Topics: Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Terminal | 1991 |
Terminal restlessness--its management and the role of midazolam.
Topics: Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Terminal | 1991 |
Midazolam for conscious sedation during pediatric oncology procedures: safety and recovery parameters.
Topics: Adolescent; Child; Child, Preschool; Conscious Sedation; Female; Humans; Infant; Male; Midazolam; Ne | 1991 |
Midazolam for conscious sedation during pediatric oncology procedures: safety and recovery parameters.
Topics: Adolescent; Child; Child, Preschool; Conscious Sedation; Female; Humans; Infant; Male; Midazolam; Ne | 1991 |
Subcutaneous midazolam infusion in palliative care.
Topics: Adult; Aged; Female; Humans; Infusions, Parenteral; Male; Midazolam; Middle Aged; Neoplasms; Psychom | 1990 |
Subcutaneous midazolam infusion in palliative care.
Topics: Adult; Aged; Female; Humans; Infusions, Parenteral; Male; Midazolam; Middle Aged; Neoplasms; Psychom | 1990 |